Regeneron Pharmaceuticals Inc (REGN) Event Aug. 03, 2022, 00:00 UTC (71% Positive) REGENERON PHARMACEUTICALS, INC. (REGN) Reports 131% Profit Growth for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 10:37 a.m. 🏢 Regeneron Pharmaceuticals Inc (REGN) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-03 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $4.21B $1.83B $2.39B +130.83% 📉 Total Assets $25.43B $27.21B $-1.77B -6.51% 📉 Total Liabilities $6.67B $6.52B $148.00M +2.27% ↗️ Stockholders' Equity $15.13B $-7.22B $22.35B +309.48% 📈 Operating Income/Loss $4.46B $2.37B $2.09B +88.31% 📉 R&D Expense $1.46B $1.64B $-181.00M -11.05% 📈 SG&A Expense $820.30M $926.30M $-106.00M -11.44% 📈 Earningspersharebasic $40.06 $17.01 $23.05 +135.51% 📈 Earningspersharediluted $38.07 $16.07 $22.00 +136.90% 📈 📈 Financial Trend Analysis 💰 Profitability improved with +130.8% net income growth • ⚖️ Liability growth outpaced asset growth 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Regeneron Pharmaceuticals Inc (REGN) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
💰 Profitability improved with +130.8% net income growth • ⚖️ Liability growth outpaced asset growth
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document